{"id":58543,"date":"2026-03-02T13:51:51","date_gmt":"2026-03-02T05:51:51","guid":{"rendered":"https:\/\/flcube.com\/?p=58543"},"modified":"2026-03-02T13:51:52","modified_gmt":"2026-03-02T05:51:52","slug":"sino-biopharmas-rovadicitinib-wins-nmpa-approval-first-in-class-jak-rock-inhibitor-for-myelofibrosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58543","title":{"rendered":"Sino Biopharma&#8217;s Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor for Myelofibrosis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sino Biopharmaceutical Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG:\u202f1177<\/a>)<\/strong> announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>rovadicitinib tablets (trade name: Anxu)<\/strong>, a <strong>Category\u202f1 innovative drug<\/strong>, for <strong>first\u2011line treatment<\/strong> of adult patients with <strong>intermediate\u20112 or high\u2011risk myelofibrosis<\/strong>\u2014including <strong>primary myelofibrosis (PMF)<\/strong>, <strong>post\u2011polycythemia vera myelofibrosis (PPV\u2011MF)<\/strong>, and <strong>post\u2011essential thrombocythemia myelofibrosis (PET\u2011MF)<\/strong>. The <strong>global first\u2011in\u2011class JAK\/ROCK dual inhibitor<\/strong> offers a <strong>novel mechanism<\/strong> combining <strong>anti\u2011inflammatory and anti\u2011fibrotic effects<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sino Biopharmaceutical Limited (HKG:\u202f1177)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Rovadicitinib (Anxu)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category\u202f1 innovative drug; first\u2011in\u2011class small\u2011molecule<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td><strong>JAK\/ROCK dual inhibition<\/strong><\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA marketing approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line intermediate\u20112\/high\u2011risk myelofibrosis (PMF, PPV\u2011MF, PET\u2011MF)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-dual-pathway-inhibition\">Mechanism of Action \u2013 Dual Pathway Inhibition<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Pathway<\/th><th>Target<\/th><th>Therapeutic Effect<\/th><\/tr><\/thead><tbody><tr><td><strong>JAK1\/2\u2013STAT3\/5<\/strong><\/td><td>JAK inhibition<\/td><td>Minimizes inflammatory cytokines from myeloid cells \u2192 alleviates splenomegaly and systemic symptoms<\/td><\/tr><tr><td><strong>ROCK1\/2<\/strong><\/td><td>ROCK inhibition<\/td><td>Lowers T\u2011cell polarization and pro\u2011inflammatory load \u2192 enhances anti\u2011inflammatory effect + supports long\u2011term disease control<\/td><\/tr><tr><td><strong>Combined Effect<\/strong><\/td><td>Dual JAK\/ROCK blockade<\/td><td><strong>Synergistic anti\u2011inflammation + anti\u2011fibrosis<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-ii-study-tq05105-ii-01\">Clinical Evidence \u2013 Phase II Study (TQ05105\u2011II\u201101)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Comparison<\/th><th>Rovadicitinib<\/th><th>Hydroxyurea<\/th><\/tr><\/thead><tbody><tr><td><strong>Efficacy<\/strong><\/td><td>Superior<\/td><td>Standard of care<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable<\/td><td>Established but limited efficacy in MF<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Intermediate\u20112 or high\u2011risk myelofibrosis<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class Differentiation:<\/strong> Rovadicitinib is the <strong>world&#8217;s first JAK\/ROCK dual inhibitor<\/strong>, positioning Sino Biopharma as a <strong>pioneer in myelofibrosis mechanism innovation<\/strong> beyond single\u2011target JAK inhibitors (ruxolitinib, fedratinib).<\/li>\n\n\n\n<li><strong>Dual Therapeutic Benefit:<\/strong> The <strong>anti\u2011inflammatory + anti\u2011fibrotic<\/strong> combination addresses <strong>both disease symptoms and underlying pathology<\/strong>, potentially offering <strong>superior long\u2011term disease control<\/strong> vs. JAK\u2011only therapy.<\/li>\n\n\n\n<li><strong>First\u2011Line Positioning:<\/strong> <strong>Front\u2011line approval<\/strong> in intermediate\u20112\/high\u2011risk patients\u2014vs. second\u2011line positioning for some competitors\u2014enables <strong>earlier intervention<\/strong> and broader market capture.<\/li>\n\n\n\n<li><strong>Myelofibrosis Spectrum Coverage:<\/strong> Indication spans <strong>primary MF and post\u2011MPN MF<\/strong> (PPV\u2011MF, PET\u2011MF), addressing the <strong>full disease continuum<\/strong> in myeloproliferative neoplasms.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Myelofibrosis Market<\/strong><\/td><td>~\u202f$2\u202fbillion globally; dominated by Incyte&#8217;s Jakafi (ruxolitinib) with growing competition from fedratinib, pacritinib<\/td><\/tr><tr><td><strong>JAK Inhibitor Limitations<\/strong><\/td><td>Existing therapies control symptoms but limited impact on fibrosis; rovadicitinib&#8217;s ROCK component addresses unmet pathological need<\/td><\/tr><tr><td><strong>China Market Dynamics<\/strong><\/td><td>Category\u202f1 status supports premium pricing; first\u2011line positioning captures treatment\u2011na\u00efve patients before competitor penetration<\/td><\/tr><tr><td><strong>Pipeline Expansion<\/strong><\/td><td>JAK\/ROCK platform may support development in other fibro\u2011inflammatory diseases (scleroderma, IPF)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market share capture, and label expansion potential for rovadicitinib. Actual results may differ due to risks including competitive JAK inhibitor pricing, physician adoption curves, and long\u2011term safety monitoring requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030200006_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030200006_c.\"><\/object><a id=\"wp-block-file--media-6ba1a1f1-0a71-4b28-9693-cda9668f0e6c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030200006_c.pdf\">2026030200006_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030200006_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6ba1a1f1-0a71-4b28-9693-cda9668f0e6c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that the National Medical Products Administration (NMPA) has approved rovadicitinib&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58546,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[908,15,313],"class_list":["post-58543","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-1177","tag-product-approvals","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharma&#039;s Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor for Myelofibrosis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that the National Medical Products Administration (NMPA) has approved rovadicitinib tablets (trade name: Anxu), a Category\u202f1 innovative drug, for first\u2011line treatment of adult patients with intermediate\u20112 or high\u2011risk myelofibrosis\u2014including primary myelofibrosis (PMF), post\u2011polycythemia vera myelofibrosis (PPV\u2011MF), and post\u2011essential thrombocythemia myelofibrosis (PET\u2011MF). The global first\u2011in\u2011class JAK\/ROCK dual inhibitor offers a novel mechanism combining anti\u2011inflammatory and anti\u2011fibrotic effects.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58543\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharma&#039;s Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor for Myelofibrosis\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that the National Medical Products Administration (NMPA) has approved rovadicitinib tablets (trade name: Anxu), a Category\u202f1 innovative drug, for first\u2011line treatment of adult patients with intermediate\u20112 or high\u2011risk myelofibrosis\u2014including primary myelofibrosis (PMF), post\u2011polycythemia vera myelofibrosis (PPV\u2011MF), and post\u2011essential thrombocythemia myelofibrosis (PET\u2011MF). The global first\u2011in\u2011class JAK\/ROCK dual inhibitor offers a novel mechanism combining anti\u2011inflammatory and anti\u2011fibrotic effects.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58543\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T05:51:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T05:51:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0206.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharma&#8217;s Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\\\/ROCK Inhibitor for Myelofibrosis\",\"datePublished\":\"2026-03-02T05:51:51+00:00\",\"dateModified\":\"2026-03-02T05:51:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0206.webp\",\"keywords\":[\"HKG: 1177\",\"Product approvals\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58543#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58543\",\"name\":\"Sino Biopharma's Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\\\/ROCK Inhibitor for Myelofibrosis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0206.webp\",\"datePublished\":\"2026-03-02T05:51:51+00:00\",\"dateModified\":\"2026-03-02T05:51:52+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that the National Medical Products Administration (NMPA) has approved rovadicitinib tablets (trade name: Anxu), a Category\u202f1 innovative drug, for first\u2011line treatment of adult patients with intermediate\u20112 or high\u2011risk myelofibrosis\u2014including primary myelofibrosis (PMF), post\u2011polycythemia vera myelofibrosis (PPV\u2011MF), and post\u2011essential thrombocythemia myelofibrosis (PET\u2011MF). The global first\u2011in\u2011class JAK\\\/ROCK dual inhibitor offers a novel mechanism combining anti\u2011inflammatory and anti\u2011fibrotic effects.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58543\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0206.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0206.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharma's Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\\\/ROCK Inhibitor for Myelofibrosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58543#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharma&#8217;s Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\\\/ROCK Inhibitor for Myelofibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharma's Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor for Myelofibrosis - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that the National Medical Products Administration (NMPA) has approved rovadicitinib tablets (trade name: Anxu), a Category\u202f1 innovative drug, for first\u2011line treatment of adult patients with intermediate\u20112 or high\u2011risk myelofibrosis\u2014including primary myelofibrosis (PMF), post\u2011polycythemia vera myelofibrosis (PPV\u2011MF), and post\u2011essential thrombocythemia myelofibrosis (PET\u2011MF). The global first\u2011in\u2011class JAK\/ROCK dual inhibitor offers a novel mechanism combining anti\u2011inflammatory and anti\u2011fibrotic effects.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58543","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharma's Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor for Myelofibrosis","og_description":"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that the National Medical Products Administration (NMPA) has approved rovadicitinib tablets (trade name: Anxu), a Category\u202f1 innovative drug, for first\u2011line treatment of adult patients with intermediate\u20112 or high\u2011risk myelofibrosis\u2014including primary myelofibrosis (PMF), post\u2011polycythemia vera myelofibrosis (PPV\u2011MF), and post\u2011essential thrombocythemia myelofibrosis (PET\u2011MF). The global first\u2011in\u2011class JAK\/ROCK dual inhibitor offers a novel mechanism combining anti\u2011inflammatory and anti\u2011fibrotic effects.","og_url":"https:\/\/flcube.com\/?p=58543","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T05:51:51+00:00","article_modified_time":"2026-03-02T05:51:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0206.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58543#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58543"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharma&#8217;s Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor for Myelofibrosis","datePublished":"2026-03-02T05:51:51+00:00","dateModified":"2026-03-02T05:51:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58543"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58543#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0206.webp","keywords":["HKG: 1177","Product approvals","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58543#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58543","url":"https:\/\/flcube.com\/?p=58543","name":"Sino Biopharma's Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor for Myelofibrosis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58543#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58543#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0206.webp","datePublished":"2026-03-02T05:51:51+00:00","dateModified":"2026-03-02T05:51:52+00:00","description":"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that the National Medical Products Administration (NMPA) has approved rovadicitinib tablets (trade name: Anxu), a Category\u202f1 innovative drug, for first\u2011line treatment of adult patients with intermediate\u20112 or high\u2011risk myelofibrosis\u2014including primary myelofibrosis (PMF), post\u2011polycythemia vera myelofibrosis (PPV\u2011MF), and post\u2011essential thrombocythemia myelofibrosis (PET\u2011MF). The global first\u2011in\u2011class JAK\/ROCK dual inhibitor offers a novel mechanism combining anti\u2011inflammatory and anti\u2011fibrotic effects.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58543#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58543"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58543#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0206.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0206.webp","width":1080,"height":608,"caption":"Sino Biopharma's Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor for Myelofibrosis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58543#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharma&#8217;s Rovadicitinib Wins NMPA Approval \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor for Myelofibrosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0206.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58543"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58543\/revisions"}],"predecessor-version":[{"id":58549,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58543\/revisions\/58549"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58546"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}